Evaluation Of Naturally Occurring Resistance To Direct Acting Antiviral Drugs (DAAs) In Individuals With Acute Hepatitis C Infection
Funder
National Health and Medical Research Council
Funding Amount
$333,778.00
Summary
Hepatitis C therapy in the future is likely to involve the use of Directly Acting Antivirals, which offer a better chance of treatment success and shorter treatment courses. The downside to these new agents is the possible development of drug resistance. Studies suggest that drug resistant strains may already exist in some individuals prior to treatment. This study plans to use sensitive methods to examine how common drug resistant strains are in untreated individuals with acute hepatitis C.
Improving The Health Of People With Problematic Drug Use: Hepatitis C And Drug Dependence
Funder
National Health and Medical Research Council
Funding Amount
$9,060,140.00
Summary
Problematic drug use is the major risk factor to health among Australians aged 15-49 years. The dual harms of drug dependence and hepatitis C virus (HCV) faced by people who use drugs compel improved drug dependence management and HCV prevention and treatment. This Program Grant will improve the lives of people with problematic drug use by investigating health impacts of drug use and evaluating new strategies for managing drug dependence and eliminating HCV among people who use drugs.
Studies On The Pathogenesis And Treatment Outcomes Of Chronic Viral Hepatitis
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
The global impact of hepatitis B and hepatitis C has recently been recognized by the World Health Organization. The Fellowship will support a research program that will use new technologies to answer a number of important questions concerning the pathogenesis of viral hepatitis B and C, interferon treatment response for HCV, and antiviral drug resistance. The outcomes of the research will be timely, clinically relevant, and of great interest to the international community. The ultimate goal is t ....The global impact of hepatitis B and hepatitis C has recently been recognized by the World Health Organization. The Fellowship will support a research program that will use new technologies to answer a number of important questions concerning the pathogenesis of viral hepatitis B and C, interferon treatment response for HCV, and antiviral drug resistance. The outcomes of the research will be timely, clinically relevant, and of great interest to the international community. The ultimate goal is to improve clinical outcomes for patients.Read moreRead less
ANTIVIRAL DRUG RESISTANT HBV: PATHOGENIC AND ONCOGENIC SIGNIFICANCE OF THE ALTERED VIRAL ENVELOPE
Funder
National Health and Medical Research Council
Funding Amount
$509,284.00
Summary
We aim to investigate the consequences of long-term therapy for hepatitis B on liver cancer progression. We propose that antiviral therapy is associated with persistent expression and accumulation of potentially oncogenic surface proteins in the liver. This can dramatically alter the viral lifecycle, particularly the HBsAg secretion pathway, which can cause serious effects in the host hepatocyte biology, including promoting pathways to tumour formation.
Hepatitis B Virus Drug Resistance: Impact On The Immunisation Program
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
ñAntiviral drug-associated vaccine escape mutantsî have the potential to jeopardize the hepatitis B immunization program. Which particular viral mutations or combination of mutations that can directly affect the clinical outcome of infection, especially in the context of vaccine induced immunity, are not known. In this study we will identify the clinical sequelae and public health consequences arising from the selection of these mutants.
Prevention And Treatment Of Viral Hepatitis Amongst Prisoners
Funder
National Health and Medical Research Council
Funding Amount
$1,102,510.00
Summary
Hepatitis B and C infection rates remain very high in some Australian populations, notably prisoners. As this group cycles frequently back to the general community, prevention of transmission is critical. Antiviral treatment uptake remains very low in Australia, yet the prison environment offers a unique opportunity to address this. This project aims to assess effectiveness of existing prevention strategies, guide new control measures, and to evaluate a novel nurse-led model for treatment.